HAIER BIOMEDICAL(688139) 搜狐财经·2025-05-06 12:56Company Overview - Qingdao Haier Biomedical Co., Ltd. focuses on providing optimal user experiences for life science users, including pharmaceutical and biological enterprises, research institutions, hospitals, and public health organizations [2] - The company has developed two main business segments: life sciences and medical innovation, offering comprehensive digital solutions such as smart laboratories and digital hospitals [2] Financial Performance - For Q1 2025, the company reported revenue of 689 million yuan, a year-on-year increase of 0.30%, and a net profit of 110 million yuan, representing a year-on-year decrease of 19.88% [3] - The gross profit margin for the period was 48.35% [3] Market Position - As of May 6, the company's stock closed at 31.95 yuan, with a rolling price-to-earnings (PE) ratio of 29.94 times, and a total market capitalization of 10.159 billion yuan [1] - The average PE ratio in the medical device industry is 48.90 times, with a median of 36.41 times, placing the company at the 69th position in the industry ranking [1] Shareholder Information - As of March 31, 2025, the number of shareholders for the company was 12,793, a decrease of 453 from the previous count, with an average holding value of 352,800 yuan per shareholder and an average holding of 27,600 shares [1] Product and Innovation - The company's main products include low-temperature storage boxes, automated biological sample storage systems, and various automated medication products, among others [2] - In 2022, the company received several prestigious awards and certifications, enhancing its reputation in the life sciences and medical innovation sectors [2]